Inhibit versus Destroy: Are PROTAC Degraders the Solution to Targeting STAT3?

Lisa N Heppler1, David A Frank2

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Cancer Cell
|November 13, 2019
PubMed